- Home
- URGN vs XFLT Comparison
URGN vs XFLT Comparison
Compare URGN & XFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- XFLT
- Stock Information
- Founded
- URGN 2004
- XFLT 2017
- Country
- URGN United States
- XFLT United States
- Employees
- URGN N/A
- XFLT N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- XFLT Investment Managers
- Sector
- URGN Health Care
- XFLT Finance
- Exchange
- URGN Nasdaq
- XFLT Nasdaq
- Market Cap
- URGN 465.9M
- XFLT 443.5M
- IPO Year
- URGN 2017
- XFLT N/A
- Fundamental
- Price
- URGN $9.67
- XFLT $5.50
- Analyst Decision
- URGN Strong Buy
- XFLT
- Analyst Count
- URGN 7
- XFLT 0
- Target Price
- URGN $37.21
- XFLT N/A
- AVG Volume (30 Days)
- URGN 499.1K
- XFLT 336.2K
- Earning Date
- URGN 05-12-2025
- XFLT 01-01-0001
- Dividend Yield
- URGN N/A
- XFLT 14.17%
- EPS Growth
- URGN N/A
- XFLT N/A
- EPS
- URGN N/A
- XFLT N/A
- Revenue
- URGN $90,398,000.00
- XFLT N/A
- Revenue This Year
- URGN $38.65
- XFLT N/A
- Revenue Next Year
- URGN $118.69
- XFLT N/A
- P/E Ratio
- URGN N/A
- XFLT N/A
- Revenue Growth
- URGN 9.29
- XFLT N/A
- 52 Week Low
- URGN $8.94
- XFLT $6.01
- 52 Week High
- URGN $20.70
- XFLT $7.76
- Technical
- Relative Strength Index (RSI)
- URGN 41.45
- XFLT 37.65
- Support Level
- URGN $8.94
- XFLT $5.32
- Resistance Level
- URGN $10.83
- XFLT $5.50
- Average True Range (ATR)
- URGN 0.79
- XFLT 0.21
- MACD
- URGN -0.07
- XFLT 0.00
- Stochastic Oscillator
- URGN 29.67
- XFLT 58.68
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About XFLT XAI Octagon Floating Rate & Alternative Income Term Trust of Beneficial Interest
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.